What this study is
Hypothesis: To characterize and describe disease progression and heterogeneity of the gangliosidosis diseases.
This research study seeks to develop a quantitative method to delineate disease progression for the gangliosidosis diseases (Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis) in order to better understand the natural history and heterogeneity of these diseases. Such a quantitative method will also be essential for evaluating any treatments that may become available in the future, such as gene therapy. The data from this study will be necessary to provide end-points for future therapies, guide medical decisions about treatment, provide objective measurement of treatment outcomes, and accurately inform parents regarding potential outcomes.
Study details
- Sponsor
- University of Minnesota
- Conditions
- Tay-Sachs Disease · Sandhoff Disease · Late Onset Tay-Sachs Disease · GM1 Gangliosidosis · GM2 Gangliosidosis
- Enrolling
- 52 people
- Starts
- 2010-12
- Est. completion
- 2027-03-01
- Record
- View on ClinicalTrials.gov ↗
Who can join
Sex ALLHealthy volunteers Not acceptedYou may qualify if
- Subjects must have a documented gangliosidosis disease.
- Subjects must be able to complete appropriate neuropsychological and neurobehavioral assessments.
- Late-onset gangliosidosis subjects must be able to tolerate a head MRI.
You can't join if
- There are no exclusion criteria, beyond a desire not to participate.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of Minnesota - Pediatric Genetics and Metabolism
Minneapolis, Minnesota, United States
- Jeanine R. Jarnes, PharmD · Contact612-626-5131utzx0002@umn.edu
- Jeanine R. Jarnes, PharmD · Principal investigator
- Chester B. Whitley, MD, PhD · Sub-investigator
Recruiting
Study team
Sponsor
University of Minnesota
Study ID 0801M24964
Principal investigator
Jeanine R. Jarnes, PharmD
University of Minnesota - Fairview
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.